TTRX

SEC filing TTRX Reports 92.6% EASI-50 Response Rate, 44.4% EASI-90 in 4 Weeks, GX-03 Trial Shows Favorable Safety Profile

1d ago

SEC filing TTRX Announces Peer-Reviewed Publication Demonstrating GX-03 Reduces IL-36 Dermatitis Severity by 52% (p=0.0003) in Phase 2 Model

6d ago

SEC filing TTRX Issues Press Release Regarding Regulation FD Disclosure

14d ago

News Turn Therapeutics secures up to $25M in financing from Avenue Capital Group

70d ago

SEC filing TTRX Secures $25M Loan: $7M Tranche 1, $8M Milestone Tranche 2, $10M Discretionary Tranche 3

70d ago

SEC filing TTRX Issues Press Release, Furnishes Regulation FD Disclosure, Includes Interactive Data File Exhibit

105d ago

Scanner Unusual volume (3.5x average)

125d ago